Abstracts

Rationale: Eslicarbazepine is a relatively novel antiepileptic drug (AED) which blocks Sodium channels. It is structurally similar to Oxcarbazepine and is licenced for focal epilepsy. Eslicarbazepine has a good safety and efficacy profile and is available as a once daily preparation. The aim of this study is to assess the practical effects of eslicarbazepine on a relatively specialised epilepsy population. In practice, clinicians and patients may not follow the clinical course as in Randomised controlled trials (RCT), obseravational and cohort studies may be used to used to review how this drug is used in clinics. Methods: Retrospective analysis of all patients >age 16 who have been commenced on Eslicarbazepine between 2009 and Oct 2015 in two large teaching hospitals in Dublin, Ireland. Data were collected via a review of the electronic patient record. Data collected included demographics, seizure types, seizure frequency, concomitant AED, Sodium measurement prior to and during treatment period. Data were analysed using Microsoft Access, Microsoft Excel and SPSS Results: There were a total of 263 patients identified who were prescribed eslicarbazepine prior to Oct 2015. Please note that the following are provisional results up to the current date. We will complete full analysis at a later time in addition to selective chart review to clarify missing data. We have clinical information on 34 patients and sodium measurements on 67 patients. Mean Na prior to Eslicarbazepine: 137.2 (SD: 32), Mean Na during treatment with Eslicarbazepine: 135.6 (SD: 6). Results were analysed using a paired student's T test, p value was 0.262, therefore no statistical significance. Eslicarbazepine was discontinued in 52.9% of patients, with the most common cause of discontinuation being poor efficacy. Additional statistics and demographics are viewable in the supplemental graphs, which are all subject to change as we analyse more patients. Conclusions: It is difficult to make a definitive conclusion with an incomplete data set. There is no significant change in Sodium upon commencement of Eslicarbazepine. A 35% of clinicians felt that patient improved with Eslicarbazepine on a subjective basis. We will finish a complete analyisis of all of the patients in time for the meeting in Dec 2016. Funding: Nil